csxb-nt10q0508.htm
SECURITIES
& EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
12b-25
Notification
of Late Filing
CHINA
SXAN BIOTECH, INC.
Commission
File Number 0-27175
(Check
one)
[
] Form 10-K and Form 10-KSB [
] Form 11-K [
] Form 20-F
[X] Form 10-Q
and Form 10-QSB [
] Form N-SAR [
] Form N-CSR
For the
period ended: March 31, 2008
[
] Transition Report on Form 10-K and Form 10-KSB
[
] Transition Report on Form 20-F
[
] Transition Report on Form 11-K
[
] Transition Report on Form 10-Q and Form 10-QSB
[
] Transition Report on Form N-SAR
For the
transition period ended:
-------------
Nothing
in this form shall be construed to imply that the Commission has verified
any information contained herein.
If the
notification relates to a portion of the filing checked above, identify
the
item(s) to which the notification relates:
PART
I
REGISTRANT
INFORMATION
Full name
of Registrant CHINA SXAN BIOTECH,
INC.
Former
name, if
applicable __________________________
c/o
American Union Securities, Inc.
100 Wall Street,
15th Floor, New York, NY
10005
Address of principal
executive office
PART
II
If the
subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following
should be completed. (Check box if appropriate) [X]
(a)
The reasons described in reasonable detail in Part III of this form could not be
eliminated without unreasonable effort or expense;
(b)
The subject annual report, semi-annual report, transition report on Form
10-K
10-KSB, 20-F, 11-K, Form N-SAR or Form N-CSR, or portion thereof will be filed
on or before the 15th calendar day following the prescribed due date; or the
subject quarterly report or transition report on Form 10-Q, 10-QSB,or portion
thereof will be filed on or before the fifth calendar day following the
prescribed due date; and
(c)
The accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
PART
III
NARRATIVE
China
SXAN Biotech, Inc. is unable to file its Quarterly Report on Form 10-QSB within
the required time because there was a delay in completing the adjustments
necessary to close its books for the quarter.
PART
IV
OTHER
INFORMATION
(1) Name
and telephone number of person to contact in regard to this notification: Peter
Zhou 212-232-0120
(2) Have
all other periodic reports required under Section 13 or 15(d) or the
Securities
Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940
during the preceding 12 months or for such shorter period that the
registrant
was required to file such report(s) been filed. Yes
[X] No [ ]
(3) Is it
anticipated that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof. Yes
[ ] No [X]
If so,
attach an explanation of the anticipated change, both narratively and
quantitatively,
and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
CHINA
SXAN BIOTECH, INC.
______________________________________________
Name of
Registrant as Specified in its Charter
Has
caused this notification to be signed on its behalf by the undersigned
thereunto
duly authorized.
Date: May
15,
2008 By:
/s/ Feng Zhen
Xing
Feng
Zhen Xing, President